CD73/A2AR dual pharmacological targeting for early therapeutic intervention in multiple sclerosis

Overview

This research proposes a dual pharmacological strategy targeting the adenosine-producing enzyme CD73 and the adenosine A2A receptor (A2AR) as an early therapeutic intervention in multiple sclerosis (MS). MS typically begins with a clinically isolated syndrome (CIS), the first inflammatory episode in the central nervous system, and approximately 63% of CIS patients eventually develop MS. Current clinical practice cannot reliably predict which patients will progress or when, creating a critical unmet need for early interventions that could delay or prevent disease onset.

The approach is based on the role of adenosine signaling at the choroid plexus, which forms the structural basis of the blood-cerebrospinal fluid barrier. When adenosine signaling via A2AR increases at this barrier, it becomes more permeable, allowing autoreactive T cells to infiltrate the CNS. By simultaneously blocking CD73 (which produces adenosine) and A2AR (which mediates its effects), the integrity of this barrier can be strengthened, potentially conferring resistance to MS development during the earliest disease window.

Technical specifications

Key research findings supporting the approach:

• CD73 knockout mice do not develop disease in an established animal model of MS
• A2AR agonists decrease choroid plexus barrier integrity, while A2AR antagonists strengthen it
• CD73 and A2AR expression increases markedly in choroid plexus cells well before the first motor symptoms appear
• Increased vascular A2AR immunoreactivity has been observed in active MS lesions in human postmortem brain tissue
• In vitro studies show that combined treatment with the CD73 inhibitor APCP and the selective A2AR antagonist Istradefylline completely restored inflammatory gene expression to control levels in the neurovascular unit under neuroinflammatory conditions
• CD73 and A2AR have complementary rather than redundant functions, making dual targeting essential

Proposed in vivo validation methodology:

• Testing in Dark Agouti rats, selected for well-defined genetic characteristics and high susceptibility to experimental autoimmune encephalomyelitis (EAE)
• Daily motor and sensory performance assessment using standardized neurological scales
• Treatment with 2 mg/kg APCP and 4 mg/kg Istradefylline via oral gavage for seven consecutive days, beginning at 3 days post-induction (before motor symptoms appear at 9 days)
• Assessment of choroid plexus integrity and EAE pathology using molecular biology and imaging techniques

Technology readiness level

This research is at the preclinical validation stage. Strong preliminary in vitro data have been generated, demonstrating that dual CD73/A2AR pharmacological targeting attenuates inflammatory responses in the neurovascular unit. The proposed next phase involves in vivo validation in an established animal model of MS, with the goal of demonstrating that early intervention can prevent or delay disease onset. The use of Istradefylline, an A2AR antagonist already approved for clinical use in Parkinson's disease, may accelerate the translational pathway. Success in animal model validation would establish the foundation for potential clinical development of this dual-targeting approach for early MS intervention.